Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/ijms19051304
Keywords
animal models; biomarkers; clinical trials; congenital disorders of glycosylation (CDG); diagnosis; dietary supplementation; mannose; galactose; pharmacological chaperones; therapy
Funding
- CDG Professionals and Patient Associations International Network (CDG AlliesPPAIN)
- FundacAo para a Ciencia e Tecnologia (FCT) [SFRH/BD/124326/2016]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/124326/2016] Funding Source: FCT
Ask authors/readers for more resources
Congenital disorders of glycosylation (CDG) are a group of genetic disorders that affect protein and lipid glycosylation and glycosylphosphatidylinositol synthesis. More than 100 different disorders have been reported and the number is rapidly increasing. Since glycosylation is an essential post-translational process, patients present a large range of symptoms and variable phenotypes, from very mild to extremely severe. Only for few CDG, potentially curative therapies are being used, including dietary supplementation (e.g., galactose for PGM1-CDG, fucose for SLC35C1-CDG, Mn2+ for TMEM165-CDG or mannose for MPI-CDG) and organ transplantation (e.g., liver for MPI-CDG and heart for DOLK-CDG). However, for the majority of patients, only symptomatic and preventive treatments are in use. This constitutes a burden for patients, care-givers and ultimately the healthcare system. Innovative diagnostic approaches, in vitro and in vivo models and novel biomarkers have been developed that can lead to novel therapeutic avenues aiming to ameliorate the patients' symptoms and lives. This review summarizes the advances in therapeutic approaches for CDG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available